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The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the effects of the angiotensin II receptor blocker candesartan and the calcium channel blocker amlodipine on the incidence of CV events in Japanese high-risk hypertensive patients. 5, 6 The CASE-J trial found that candesartan and amlodipine equally suppressed total CV mortality and morbidity in high-risk hy-
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pertensive patients under strict blood pressure (BP) control. Although some Japanese cohort studies have been performed to clarify the coronary risk factors, this trial was an observational study irrespective of allocated drugs, and the purpose of the present subanalysis was to clarify the adverse effects of coronary risks in Japanese high-risk hypertensive patients. Although prior cohort studies focused on the general population, the present study focused on those subjects taking anti-hypertensive drugs. Therefore, the influence of risk factors on coronary events under control could be clarified.
Methods

Study Design
The CASE-J trial was a prospective, multicenter, randomized, open-label, active-controlled, 2-arm parallel-group comparison study to evaluate the efficacy of candesartan and amlodipine for reducing the incidence of CV events in high-risk hypertensive patients. 5, 6 The rationale and complete design of the CASE-J trial have been previously reported. 5 Briefly, 4,728 patients with high-risk hypertension were randomly assigned to either a candesartan-or amlodipine-based treatment regimen. High risk was defined as the presence of any one of the following: (1) severe hypertension (systolic BP/ diastolic BP [SBP/DBP] ≥180/110 mmHg; (2) type 2 diabetes mellitus (DM); (3) history of stroke or transient ischemic attack >6 months prior to screening; (4) left ventricular hypertrophy (LVH; SV1+ RV5 ≥3.5 mV on electrocardiography [ECG] and/or LV wall thickness ≥12 mm on echocardiography), angina pectoris, or a history of myocardial infarction >6 months prior to screening; (5) proteinuria or serum creatinine concentration ≥1.3 mg/dl; and (6) arteriosclerotic peripheral artery obstruction. 5 The target BP was determined according to the guideline proposed by the Japanese Society of Hypertension. 7 Finally, 4,703 randomly assigned patients were included in the analysis. 
Outcome Measurements
In the CASE-J trial, the primary endpoint was the first fatal/ non-fatal CV event (a composite of cardiac events including sudden death, angina pectoris, acute myocardial infarction, or heart failure; cerebrovascular events including stroke or transient ischemic attack; renal events including serum creatinine concentration ≥4.0 mg/dl, doubling of the serum creatinine concentration, or end-stage renal disease; and vascular events including dissecting aortic aneurysm or arteriosclerotic occlusion of a peripheral artery). 6 In the present subanalysis, we focused on the incidence of coronary events. Thus, the endpoint of this subanalysis was coronary events, and they were defined as a composite of sudden death (unexpected death happening within 24 h without external causes), angina pectoris (nitrate-sensitive chest pain and ischemic ECG changes during chest pain or stress testing), and acute myocardial infarction (nitrate-resistant chest pain, elevated myocardial specific enzymes, and typical ECG signs). Event evaluation was performed independently by the Event Evaluation Committee, which was blinded to the assigned treatment groups and adjudicated according to the prespecified protocol criteria as described here. 6
Baseline Characteristics
Background coronary risk factors such as gender, age, allocated drugs, body mass index (BMI), SBP, DBP, smoking, type 2 DM, hyperlipidemia (HL), LVH, history of previous IHD, history of cerebrovascular disease, chronic kidney disease (CKD), and anti-hypertensive medication prior to the screening were analyzed ( Table 1 ). Baseline characteristics of enrolled patients are listed in Table 2 . Moreover, we focused on the presence or absence of previous IHD including angina pectoris, and a past history (≥6 months before giving informed consent) of myocardial infarction, which were 1 of the inclusion criteria in the CASE-J trial. Enrolled patients were divided into 4,107 patients without previous IHD and 596 patients with previous IHD. In the present study, risk factors for the first coronary event were assessed in patients without previous IHD and those for the recurrence of coronary events were done in patients with previous IHD. Their baseline characteristics are also given in Table 2 . When we analyzed the data of patients with or without coronary risk factors as an observational study irrespective of allocated drugs, there were statistical differences between these 2 groups. Analyses were then adjusted by baseline characteristics as described in the following section.
Statistical Analysis
Data are expressed as mean ± SD or proportions. Risk-adjusted cumulative incidence of coronary events was calculated using the corrected group prognosis method, 8 with adjustment for baseline characteristics, including history of prior anti-hypertensive treatment, allocated drugs, age, sex, BMI, type 2 DM, history of cerebrovascular disease, history of IHD, renal dysfunction, history of vascular disease, SBP and DBP at baseline. The hazard ratio (HR) and 95% confidence intervals (95%CIs) were estimated using Cox regression analysis. We also used multiple Cox regression analysis to examine the association between rate of coronary events and coronary risk factors (gender, age, allocated drugs, BMI, SBP, DBP, smoking, DM, HL, LVH, previous IHD, previous cerebrovascular disease, CKD, and previous anti-hypertensive medication). All statistical tests were 2-sided with an alpha level of 0.05, and were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA). 
Results
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Cumulative incidence of the primary composite endpoint adjusted for baseline characteristics in patients without ischemic heart disease (IHD) at baseline and with IHD at baseline. UESHIMA K et al. Figure) . We also evaluated the prognostic value of the coronary risk factors in all enrolled patients. As shown in In addition, the prognostic value of the coronary risk factors for each event category was evaluated in patients without previous IHD (primary prevention) and in patients with previous IHD (secondary prevention), respectively. As shown in Table 5 ). Although a significant difference was observed in the risk factors between primary prevention and secondary prevention, interactions between the coronary risk factors and previous IHD were not significant except for HL. Notably, DM was the common predictor of coronary events both in primary and secondary prevention.
Discussion
Increases in BP loads induce myocardial remodeling, such as cardiac hypertrophy, myocardial fibrosis and coronary endothelial damage. Progression of myocardial remodeling and coronary atherosclerosis leads to coronary artery disease, heart failure, arrhythmia and sudden death. In men, morbidity and mortality rates due to coronary artery disease increase by approximately 15% with a 10-mmHg increase in SBP. 9 Conventional anti-hypertensive drug therapy primarily using diuretics and β-blockers, however, does not markedly reduce the incidence of coronary artery disease, whereas it markedly decreases the incidence of stroke. 10 Coronary risk factors other than hypertension may have a markedly different impact on the occurrence of coronary artery disease. 11 Accordingly, the aim of the present study was to clarify the influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients as a subanalysis of the CASE-J trial. The follow-up rate and coronary event evaluation are markedly reliable from this cohort study. Furthermore, although some 
Coronary Risk Factor in Japanese Hypertensives
Japanese cohort studies were performed to clarify coronary risk factors, 12-16 this subanalysis focused on the subjects under anti-hypertensive treatment. Therefore, the adverse effects of coronary risk factors under BP control could be evaluated. First, we demonstrated that a history of previous IHD was the strongest predictor for coronary events in all enrolled patients. Because the prognosis of patients with previous IHD is worse, a sufficient reduction of BP in these patients is important to decrease CV events and mortality. 6,17, 18 In the Japan Lipid Intervention Trial, the incidence of coronary events in patients with a history of IHD was 5-fold higher than in patients without this. 19 In addition, Iso reported that the percentage of preventable IHD was 34% in men and 17% in women for control of hypertension. 8 A total of 80-90% of hypertensive patients in their 30 s and 40 s, however, are untreated in Japan. 9 For reduction of coronary events, population-wide health education is needed for prevention of high BP through lifestyle modifications.
With regard to primary prevention, we also found that DM, HL, and DBP decrease at baseline were significant predictors of occurrence of CV events. DM is well known to be 1 of the most important causes of CV events. Berman et al identified a significant impact of DM on cardiac risk and found that diabetic women have a significantly greater risk of cardiac death than other patients. 20 Haffner et al found that diabetic patients without previous myocardial infarction in a Finnish population-based study had as high a risk of myocardial infarction as non-diabetic patients with previous myocardial infarction. 21 In Japanese people, Nishimura et a; also demonstrated that the CV event rates were similar among nondiabetic patients with prior myocardial infarction and diabetic patients without prior myocardial infarction. 22 It is also well established that HL is a major cause of IHD. According to a Japanese autopsy study, the myocardial infarction size among urban men with HL was large, as also observed in Western populations. 23 Mabuchi et al found that patients with a total cholesterol concentration ≥240 mg/dl developed coronary heart disease more often than patients with total cholesterol <240 mg/dl. 19 The serum low-density lipoprotein cholesterol concentration positively correlated with incidence of the coronary events. The percentage of preventable coronary heart disease was 5% in men and 9% in women for control of DM, and 5% in men and 8% in women for control of HL. 8 In the present study, the lower DBP was extracted from the database as a significant predictor of coronary events. Several observational studies have provided evidence suggesting that pulse pressure was a better predictor of CV events than mean pressure. [24] [25] [26] In the Multiple Risk Factor Intervention Trial, the greatest risk was observed in subjects with the highest SBP (≥160 mmHg) and lowest DBP (<70 mmHg) at enrollment. Furthermore, the 2-year probability of a major CV endpoint increased with lower DBP at any given level of SBP. 26 Because patients at high risk of coronary events had increased arterial stiffness, lower DBP was identified as a significant marker of coronary events. We also reported that a strong association with risk of new-onset DM was seen in patients with higher pulse pressures, arising mainly due to the lower DBP. 27 With regard to secondary prevention, we demonstrated that male sex, CKD, and DM were significant predictors for coronary events. Hypertension causes functional or structural changes to varying degrees in the kidney from an early stage, and renal dysfunction may also cause hypertension. Renal dysfunction and proteinuria are known to be risk factors for end-stage renal failure, 28,29 but they have also recently been found to be strong risk factors for CV disease. 16,30, 31 The concept of CKD was introduced for preventing the occurrence of CV disease as well as renal insufficiency by the early detection and treatment of renal diseases. 32 Therefore, strict management of BP as well as treatment of the underlying renal disease is important.
Prevention and treatment for glucose normalization is important in not only primary prevention for coronary events but also in secondary prevention. Elevated blood glucose levels on admission are associated with increased mortality in patients with acute myocardial infarction. In the J-ACCESS study, patients with suspected or confirmed IHDs were classified into 4 groups according to DM and prior myocardial infarction. The prognosis was worst among diabetic patients with prior myocardial infarction. 22 Because the risks of CV events in patients with DM, who achieved SBP/DBP <130/75-79 mmHg, were still significantly higher than in those without DM, strict BP control is needed to reduce CV events in hypertensive patients with DM. 33 In the present subanalysis, previous IHD including angina pectoris and myocardial infarction was one of the inclusion criteria in the CASE-J trial, and there were several differences in baseline characteristics between previous IHD (-) and previous IHD (+), as shown in Table 2 . Therefore, when we evaluated the data of patients with baseline coronary risk factors, the analyses had to be adjusted by the baseline characteristics because of their statistical differences. Interestingly, DM was the common predictor of coronary events both in primary and secondary prevention.
Several limitations in the present study should be noted. This was a post-hoc analysis. The number of coronary events may not be sufficient to analyze the influence of the coronary risk factors on these events. Furthermore, a 3.2-year mean follow-up period may not be sufficient to evaluate the relationship between underlying risks and the incidence of coronary events. The CASE-J trial was extended for 3 years from 2006, it was named the CASE-J Ex and it was an observational study. 34 The CASE-J Ex may resolve this issue. Moreover, a difference in the significant risk factors between primary and secondary prevention was observed. Moreover, because DM at baseline was diagnosed by each participant doctor, we did not evaluate specific blood sugar or HbA1c. Thus, information on the relationship between blood sugar or HbA1c and the risk of coronary events is not available. Finally, because HL was diagnosed only on taking medications for HL, there is a possibility that the influence of HL on coronary events was underestimated.
In conclusion, previous IHD, DM, male sex, CKD, and DBP decrease are significant risk factors in all enrolled patients to the CASE-J trial. Because DM, HL and DBP decrease are risk factors in patients without previous IHD, lowering blood sugar and cholesterol are still important measures in terms of primary prevention. In addition, because male sex, CKD and DM are risk factors in patients with previous IHD, CKD and DM are important issues in terms of secondary prevention. Although there are some differences in the coronary risk factors between primary and secondary prevention in Japanese high-risk hypertensive patients, DM is the important factor in both primary and secondary prevention. Furthermore, comprehensive risk management including surveillance of DM, CKD and HL is needed for preventing coronary events, in addition to BP control. General and particular care of lifestyle-related disease leads to prevention of IHD.
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